Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN65,365,321,18
Msft3,07
Nokia4,35054,4043,57
IBM-4,48
Mercedes-Benz Group AG68,368,311,04
PFE-1,82
26.01.2023 23:41:33
Indexy online
AD Index online
select
AD Index online
 

  • 26.01.2023 17:35:10
PureTech Health (London)
Poslední obchod Změna (%) Změna (GBP) Objem obchodů (GBP)
2,60 -1,89 -0,05 381 940
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 27.01.2023
Popis společnosti
Obecné informace
Název společnostiPuretech Health PLC
TickerPRTC
Kmenové akcie:Ordinary Shares
RICPRTC.L
ISINGB00BY2Z0H74
Poslední známé roční výsledky31.12.2021
Poslední známé čtvrtletní výsledky30.06.2022
Počet zaměstnanců k 31.12.2021 95
Akcie v oběhu k 30.11.2022 278 566 306
MěnaUSD
Kontaktní informace
Ulice6 Tide Street, Suite 400
MěstoBOSTON
PSČ02210
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon16 174 822 333
Fax16174823337

Business Summary: PureTech Health plc (PureTech) is a biotherapeutics company engaged in the treatment paradigm for devastating diseases. The Company has created a pipeline through its experienced research and development team and its network of scientists, clinicians, and industry leaders. The pipeline, which is being advanced both internally and through PureTech's Founded Entities, is comprised of 27 therapeutics and therapeutic candidates, including two that have received both United States (U.S.) Food and Drug Administration (FDA) clearance and European marketing authorization. All of the underlying programs and platforms that resulted in the pipeline of therapeutic candidates are identified or discovered and then advanced by the PureTech team through key validation points based on insights in immunology and drug development. The Company's wholly owned pipeline consists of various programs, including LYT-100, LYT-200, LYT-210, LYT-300, LYT-500, LYT-510, and LYT-503/IMB-150.
Financial Summary: BRIEF: For the six months ended 30 June 2022, Puretech Health PLC revenues increased 20% to $7M. Net loss decreased 62% to $28.3M. Revenues reflect Controlled Founded En segment increase of 46% to $4.8M, Parent company & other segment increase from $105K to $328K. Lower net loss reflects Gain/Loss on Derivatives - Hedging increase from $12.5M (expense) to $55.2M (income), Equity Earnings Net of Income Tax decrease of 80% to $15.3M (expense).
Odvětvová klasifikace
TRBC2012Biotechnology & Medical Research (NEC)
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)
NAICS2007Research and Development in Biotechnology
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICCommercial Physical Research



  • Poslední aktualizace: 27.01.2023
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Business, Legal and Operating Officer, Executive Director, Company SecretaryBharatt Chowrira5501.02.2021
Chief Executive Officer, Co-Founder, DirectorDaphne Zohar52
Co-Founder, Non-Executive DirectorRobert Langer73
Chief Financial OfficerGeorge Farmer-01.01.202101.01.2021
Chief Scientific OfficerJoseph Bolen6620.10.201620.10.2016
Chief Innovation and Strategy OfficerEric Elenko-
Chief Medical OfficerJulie Krop5413.08.202113.08.2021